Strategy for prevention of uterine leiomyoma recurrence in combination with adenomiosis after organ-conserving operations in reproductive aged women

In: Reproductive Endocrinology · 2019 · vol. 0(49) , pp. 12–16 · doi:10.18370/2309-4117.2019.49.12-16 · W2994589098
article OA: diamond CC0 ⤵ 2 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-10

This study investigated a suppressive therapy combining GnRH agonists, oral contraceptives, and adjunctive enzymes/herbs for women with uterine leiomyoma and adenomyosis after myomectomy, finding it reduced recurrence and improved reproductive function.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-10

The paper studied 76 reproductive-aged women who underwent organ-preserving surgery for uterine leiomyoma (myomectomy), comparing outcomes between those with isolated leiomyoma and those with leiomyoma combined with adenomyosis. Participants were assigned to different perioperative strategies that included pre-surgical and post-surgical GnRH agonist therapy for 3 months (with some groups receiving no pre-surgical suppressive therapy), and post-surgical low-dose combined oral contraceptives; group IIb additionally received non-hormonal therapy (streptokinase/streptodornase and an herbal antiproliferative agent containing indole-3-carbinol and epigallocatechin-3-gallate), with treatment selection justified by Ki-67, estrogen/progesterone receptors, and COX-2 immunohistochemistry. Women without suppressive therapy before surgery showed significantly higher Ki-67 expression, especially in leiomyoma nodes with adenomyosis, and COX-2 expression was markedly higher in the combined pathology; the authors report that long-term suppressive therapy reduced tumor relapses by about 2.6-fold and improved reproductive function in about one-third of women, while GnRH agonists did not reduce estrogen and progesterone receptor expression. Relevance to endometriosis: while the title and methods focus on adenomyosis, the study is framed within a broader uterine hyperproliferative/endometriosis literature and lists references on genital endometriosis and chronic pelvic pain, though endometriosis itself is not directly investigated in this cohort. This paper is centrally about endometriosis? No—the paper is centrally about adenomyosis — [specifically adenomyosis combined with uterine leiomyoma after organ-conserving myomectomy and postoperative suppressive therapy].

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Aim of the study: to reduce the number of relapses and improve the reproductive function of women after surgical removal of uterine leiomyoma (LM).Materials and methods: the study included 76 women of reproductive age who underwent organ-preserving surgical treatment for LM. Women were divided into two groups depending on the adenomyosis presence. Group I included 35 women with isolated LM, group II included 41 women with LM in combination with adenomyosis. Groups I and II were divided into 4 subgroups: in Ia and IIa subgroups during preparation for surgery patients received one of the agonists of gonadotropin releasing hormone (GnRH) for 3 months. In Ib and IIb subgroups suppressive therapy was not performed prior to surgical treatment. After a myomectomy women of I and II groups received one of the GnRH agonists for the first three months, followed by the low-dose combined oral contraceptive. The choice of funds was justified on the results of an immunohistochemical study of the Ki-67 antigen expression (proliferation marker), estrogen and progesterone receptors, and cyclooxygenase-2 (COX-2). Group IIb women were additionally prescribed non-hormonal therapy with fibrinolytic (streptokinase) and proteolytic (streptodornase) enzymes, as well as herbal antiproliferative agent containing indole-3-carbinol and epigallocatechin-3-gallate.Results of the study: an immunohistochemical study showed that in women who did not receive suppressive therapy before surgery (Ib and IIb groups) Kі-67 antigen expression in the tumor nodes was significantly increased. Almost 2 times greater was the difference between the Ki-67 antigen expressions in the LM nodes with the adenomyosis combination. GnRH agonists did not inhibit the expression of estrogen and progesterone receptors. COX-2 expression was significantly higher than in intact myometrium. In women with combined uterine pathology the number of cells with a positive immunohistochemical reaction to COX-2 was 6.4 times higher than with isolated LM. Conclusions: myomectomy surgery only partially solves the problems of reproductive health restoration in women with combined uterine pathology. The proposed long-term suppressive therapy made it possible to reduce the tumor relapses number by almost 2.6 times after surgical organ-preserving treatment and to improve reproductive function in almost every third woman.

My notes (saved in your browser only)

Condition tags

adenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (17)

Cited by (2)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK